TherapeuticsMD, Inc. (OTCQB: TXMD) today announced the pricing of its
previously announced underwritten public offering of 29,411,765 shares
of its common stock, offered at a price of $1.70 per share to the
public. The gross proceeds to TherapeuticsMD from this offering are
expected to be approximately $50.0 million, before deducting
underwriting discounts, commissions, and other estimated offering
expenses payable by TherapeuticsMD. All of the shares in the offering
are to be sold by TherapeuticsMD. The offering is expected to close on
or about March 20, 2013, subject to the satisfaction of customary
closing conditions. TherapeuticsMD has granted the underwriters a 30-day
option to purchase up to an aggregate of 4,411,765 additional shares of
common stock to cover over-allotments, if any.
Jefferies LLC acted as sole book-running manager for the offering, and
Noble Financial Capital Markets acted as co-manager.
A shelf registration statement on Form S-3 relating to the public
offering of the shares of common stock described above was filed with
the Securities and Exchange Commission ("SEC") and has been declared
effective by the SEC. A preliminary prospectus supplement relating to
the offering has been filed with the SEC and a final prospectus
supplement relating to the offering will be filed with the SEC and will
be available on the SEC's web site at www.sec.gov.
When available, copies of the final prospectus supplement may also be
obtained from the offices of Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY
10022, by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About TherapeuticsMD
TherapeuticsMD, Inc. is a women’s healthcare product company focused on
creating and commercializing products targeted exclusively for women.
The Company currently manufactures and distributes branded and generic
prescription prenatal vitamins as well as over-the-counter vitamins and
cosmetics. The Company is currently focused on conducting the clinical
trials necessary for regulatory approval and commercialization of
advanced hormone therapy pharmaceutical products designed to alleviate
the symptoms of and reduce the health risks resulting from
menopause-related hormone deficiencies.
Forward-Looking Statements
Except for the historical information contained herein, the matters
set forth in this press release, including statements regarding
TherapeuticsMD’s expectations with respect to the completion and timing
of the proposed public offering, are forward-looking statements within
the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially, including the risks and uncertainties associated with
market conditions, the satisfaction of customary closing conditions
related to the proposed public offering, risks and uncertainties
associated with TherapeuticsMD’s business and finances in general, and
other risks detailed in TherapeuticsMD’s annual report on Form 10-K
filed with the SEC on March 12, 2013, and other filings with the SEC.
These forward-looking statements are based on current information that
may change and you are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. All forward-looking statements are qualified in their
entirety by this cautionary statement, and TherapeuticsMD undertakes no
obligation to revise or update any forward-looking statement to reflect
events or circumstances after the issuance of this press release.
